July 29, 2016 / 11:56 AM / a year ago

AbbVie revenue jumps 17.8 pct on higher demand for drug Humira

July 29 (Reuters) - AbbVie Inc's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.

The company, which acquired cancer drug developer Stemcentrx, said net revenue rose to $6.45 billion in the second quarter ended June 30 from $5.48 billion, a year earlier.

Net profit increased to $1.61 billion, or 98 cents per share, from $1.37 billion, or 83 cents per share. (Reporting by Natalie Grover in Bengaluru; Editing by Kirti Pandey)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below